Chester County News and Community Website
WILMINGTON, DE — Incyte (Nasdaq: INCY) secured European Commission approval for Opzelura cream to treat moderate atopic dermatitis in certain adults, giving the Wilmington-based drugmaker a second European indication for …
Incyte Wins EU Approval for Opzelura in Atopic Dermatitis Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has expanded its Moments of Clarity program, adding six new personal stories that illuminate the lived experiences of people managing chronic immune-mediated skin conditions, …
Incyte Expands ‘Moments of Clarity’ With New Stories Spotlighting Chronic Skin Conditions Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration has approved Opzelura (ruxolitinib) cream 1.5% for children as young as two with mild to moderate …
FDA Expands Approval of Incyte’s Opzelura to Treat Pediatric Atopic Dermatitis Read MoreWAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis (AD). This randomized, …
Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment Read More